NASDAQ:VTL - Vital Therapies Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$9.37 +0.01 (+0.11 %)
(As of 05/24/2019 06:50 AM ET)
Previous Close$9.36
Today's Range$9.01 - $9.58
52-Week Range$0.15 - $9.75
Volume27,541 shs
Average Volume21.62 million shs
Market Capitalization$397.01 million
P/E RatioN/A
Dividend YieldN/A
Beta3.51
Vital Therapies, Inc., a biotherapeutic company, focuses on developing cell-based therapies for the treatment of acute forms of liver failure. The company was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc. in June 2003. Vital Therapies, Inc. was founded in 2003 and is based in San Diego, California.

Receive VTL News and Ratings via Email

Sign-up to receive the latest news and ratings for VTL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VTL
CUSIPN/A
Phone858-673-6840

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.29 per share

Profitability

Net Income$-41,470,000.00

Miscellaneous

Employees10
Market Cap$397.01 million
Next Earnings DateN/A
OptionableOptionable

Vital Therapies (NASDAQ:VTL) Frequently Asked Questions

What is Vital Therapies' stock symbol?

Vital Therapies trades on the NASDAQ under the ticker symbol "VTL."

How were Vital Therapies' earnings last quarter?

Vital Therapies (NASDAQ:VTL) announced its quarterly earnings data on Monday, March, 4th. The company reported ($0.06) earnings per share (EPS) for the quarter. View Vital Therapies' Earnings History.

What price target have analysts set for VTL?

4 brokers have issued twelve-month target prices for Vital Therapies' shares. Their predictions range from $6.00 to $18.00. On average, they expect Vital Therapies' share price to reach $12.00 in the next twelve months. This suggests a possible upside of 28.1% from the stock's current price. View Analyst Price Targets for Vital Therapies.

What is the consensus analysts' recommendation for Vital Therapies?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vital Therapies in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vital Therapies.

What are Wall Street analysts saying about Vital Therapies stock?

Here are some recent quotes from research analysts about Vital Therapies stock:
  • 1. According to Zacks Investment Research, "Vital Therapies, Inc. is a biotherapeutic company. It is focused on developing a cell-based therapy targeting the treatment of acute liver failure. The Company operates in the United States, Europe, and China. Vital Therapies, Inc. is based in San Diego, California. " (11/17/2018)
  • 2. Cantor Fitzgerald analysts commented, ": We are downgrading our rating on VTL shares from and establishing a new PT of $0.50 from $18. We had believed learnings from a post-hoc analysis of the VTL-208 Phase 2 study that were incorporated into the VTL-308 trial design could bias the outcome in a positive way. VTL has provided no specific details of the VTL-308 results, but disclosure that the trial failed to meet the primary and secondary endpoints and that development would cease is adequately informative. The company also announced that it would pursue strategic options, which we suppose could include a merger with a company seeking a U.S. public listing." (9/12/2018)
  • 3. BTIG Research analysts commented, "Q2 earnings call revolved around the upcoming topline data from its VTL-308 trial in severe alcoholic hepatitis (sAH). The data set is expected to be locked soon and topline data will be press released in the back half of September, with a conference call to follow. We see the announcement as a binary event. Although the insights discussed during May’s R&D Day left us with a better understanding of how ELAD should work, we remain cautious. With VTL-308 targeting patients who fit specific enrollment criteria that seems more likely to show a survival benefit, we see the likelihood of positive data as better than even, but nowhere near a shoo-in (perhaps 65-35)." (8/9/2018)

Has Vital Therapies been receiving favorable news coverage?

Media headlines about VTL stock have trended negative recently, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vital Therapies earned a daily sentiment score of -2.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the near future.

Who are some of Vital Therapies' key competitors?

What other stocks do shareholders of Vital Therapies own?

Who are Vital Therapies' key executives?

Vital Therapies' management team includes the folowing people:
  • Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.A, CEO, Pres & Director (Age 48)
  • Mr. Robert A. Ashley, Exec. VP & Chief Scientific Officer (Age 61)
  • Mr. Michael V. Swanson M.B.A., M.B.A, Exec. VP, CFO & Treasurer (Age 64)
  • Mr. John M. Dunn, Gen. Counsel & Sec. (Age 67)

Who are Vital Therapies' major shareholders?

Vital Therapies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.23%), Northern Trust Corp (0.83%), SG Americas Securities LLC (0.62%) and Bank of Montreal Can (0.01%). Company insiders that own Vital Therapies stock include Cheryl Cohen, Douglas Evan Godshall, Duane Nash, Jean Jacques Bienaime, John Michael Dunn, Muneer A Satter, Robert A Ashley and Terence E Winters. View Institutional Ownership Trends for Vital Therapies.

Which major investors are selling Vital Therapies stock?

VTL stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc. and Northern Trust Corp. Company insiders that have sold Vital Therapies company stock in the last year include Cheryl Cohen, Douglas Evan Godshall, Jean Jacques Bienaime and Muneer A Satter. View Insider Buying and Selling for Vital Therapies.

Which major investors are buying Vital Therapies stock?

VTL stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC and Bank of Montreal Can. Company insiders that have bought Vital Therapies stock in the last two years include Duane Nash, Jean Jacques Bienaime, John Michael Dunn, Muneer A Satter, Robert A Ashley and Terence E Winters. View Insider Buying and Selling for Vital Therapies.

How do I buy shares of Vital Therapies?

Shares of VTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vital Therapies' stock price today?

One share of VTL stock can currently be purchased for approximately $9.37.

How big of a company is Vital Therapies?

Vital Therapies has a market capitalization of $397.01 million. Vital Therapies employs 10 workers across the globe.

What is Vital Therapies' official website?

The official website for Vital Therapies is http://vitaltherapies.com/.

How can I contact Vital Therapies?

Vital Therapies' mailing address is 15222-B AVENUE OF SCIENCE, SAN DIEGO CA, 92128. The company can be reached via phone at 858-673-6840 or via email at [email protected]


MarketBeat Community Rating for Vital Therapies (NASDAQ VTL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  288 (Vote Outperform)
Underperform Votes:  215 (Vote Underperform)
Total Votes:  503
MarketBeat's community ratings are surveys of what our community members think about Vital Therapies and other stocks. Vote "Outperform" if you believe VTL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/24/2019 by MarketBeat.com Staff

Featured Article: What are no-load funds?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel